Notable Labs (NTBL) Stock Price, News & Analysis

Company Overview

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

Key Stats

• Today's Range: $0.24 to $0.31
• 50-Day Range: $0.24 to $0.48
• 52-Week Range: $0.22 to $4.24
• Volume: 2.11 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $2.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

NTBL Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Notable Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Notable Labs investors own include Algonquin Power & Utilities (AQN), LiveOne (LVO), Palatin Technologies (PTN), Frontier Group (ULCC), Adverum Biotechnologies (ADVM), Sirius XM (SIRI) and Clearside Biomedical (CLSD).

Company Calendar

• Today: 4/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NTBL
• Previous Symbol: NASDAQ:NTBL
• CIK: 1603207
• Web: www.vblrx.com
• Phone: (728) 993-5000
• Fax: 972-8993-5001
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +2,723.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,260,000.00
• Net Margins: N/A
• Pretax Margin: -3,368.05%
• Return on Equity: -80.81%
• Return on Assets: -62.86%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $313,000.00
• Price / Sales: 7.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.81 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 9,018,000
• Free Float: 9,544,000
• Market Cap: $2.24 million
• Optionable: No Data
• Beta: 0.98